Indicator type;Execution Sectors;Total
Units carrying out R&D in Biotechnology;Total;1,802
Units carrying out R&D in Biotechnology;Public Administration;119
Units carrying out R&D in Biotechnology;Higher Education;68
Units carrying out R&D in Biotechnology;Companies;1,602
Units carrying out R&D in Biotechnology;NPPI;13
% Units by type of biotechnology used: Genetic Code;Total;35.0
% Units by type of biotechnology used: Genetic Code;Public Administration;86.5
% Units by type of biotechnology used: Genetic Code;Higher Education;92.7
% Units by type of biotechnology used: Genetic Code;Companies;28.8
% Units by type of biotechnology used: Genetic Code;NPPI;23.1
% Units by type of biotechnology used: Functional Units;Total;43.9
% Units by type of biotechnology used: Functional Units;Public Administration;81.5
% Units by type of biotechnology used: Functional Units;Higher Education;97.1
% Units by type of biotechnology used: Functional Units;Companies;38.9
% Units by type of biotechnology used: Functional Units;NPPI;30.8
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;26.9
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Public Administration;66.4
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Higher Education;82.3
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Companies;21.5
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;NPPI;38.5
% Units by type of biotechnology used: Bioprocesses;Total;51.8
% Units by type of biotechnology used: Bioprocesses;Public Administration;58.8
% Units by type of biotechnology used: Bioprocesses;Higher Education;91.2
% Units by type of biotechnology used: Bioprocesses;Companies;49.5
% Units by type of biotechnology used: Bioprocesses;NPPI;53.9
% Units by type of biotechnology used: Subcellular Organisms;Total;13.8
% Units by type of biotechnology used: Subcellular Organisms;Public Administration;51.3
% Units by type of biotechnology used: Subcellular Organisms;Higher Education;66.2
% Units by type of biotechnology used: Subcellular Organisms;Companies;8.7
% Units by type of biotechnology used: Subcellular Organisms;NPPI;23.1
% Units by type of biotechnology used: Bioinformatics;Total;32.0
% Units by type of biotechnology used: Bioinformatics;Public Administration;70.6
% Units by type of biotechnology used: Bioinformatics;Higher Education;88.2
% Units by type of biotechnology used: Bioinformatics;Companies;26.9
% Units by type of biotechnology used: Bioinformatics;NPPI;23.1
% Units by type of biotechnology used: Nanobiotechnology;Total;16.9
% Units by type of biotechnology used: Nanobiotechnology;Public Administration;53.8
% Units by type of biotechnology used: Nanobiotechnology;Higher Education;75.0
% Units by type of biotechnology used: Nanobiotechnology;Companies;11.8
% Units by type of biotechnology used: Nanobiotechnology;NPPI;7.7
% Units by type of biotechnology used: Other;Total;17.1
% Units by type of biotechnology used: Other;Public Administration;8.4
% Units by type of biotechnology used: Other;Higher Education;8.8
% Units by type of biotechnology used: Other;Companies;18.0
% Units by type of biotechnology used: Other;NPPI;23.1
Units in which biotechnology activities are: Main and/or exclusive;Total;822
Units in which biotechnology activities are: Main and/or exclusive;Public Administration;36
Units in which biotechnology activities are: Main and/or exclusive;Higher Education;6
Units in which biotechnology activities are: Main and/or exclusive;Companies;773
Units in which biotechnology activities are: Main and/or exclusive;NPPI;7
Units in which biotechnology activities are: A secondary business line;Total;366
Units in which biotechnology activities are: A secondary business line;Public Administration;45
Units in which biotechnology activities are: A secondary business line;Higher Education;40
Units in which biotechnology activities are: A secondary business line;Companies;279
Units in which biotechnology activities are: A secondary business line;NPPI;2
Units in which biotechnology activities are: A necessary tool for production;Total;614
Units in which biotechnology activities are: A necessary tool for production;Public Administration;38
Units in which biotechnology activities are: A necessary tool for production;Higher Education;22
Units in which biotechnology activities are: A necessary tool for production;Companies;550
Units in which biotechnology activities are: A necessary tool for production;NPPI;4
% Units by final application areas of biotechnology use: Human Health;Total;52.1
% Units by final application areas of biotechnology use: Human Health;Public Administration;78.2
% Units by final application areas of biotechnology use: Human Health;Higher Education;91.2
% Units by final application areas of biotechnology use: Human Health;Companies;48.4
% Units by final application areas of biotechnology use: Human Health;NPPI;69.2
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Total;20.8
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Public Administration;21.0
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Higher Education;60.3
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Companies;19.1
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;NPPI;15.4
% Units by final application areas of biotechnology use: Food Products;Total;30.2
% Units by final application areas of biotechnology use: Food Products;Public Administration;23.5
% Units by final application areas of biotechnology use: Food Products;Higher Education;77.9
% Units by final application areas of biotechnology use: Food Products;Companies;28.9
% Units by final application areas of biotechnology use: Food Products;NPPI;0.0
% Units by final application areas of biotechnology use: Agriculture and Forestry;Total;26.3
% Units by final application areas of biotechnology use: Agriculture and Forestry;Public Administration;22.7
% Units by final application areas of biotechnology use: Agriculture and Forestry;Higher Education;70.6
% Units by final application areas of biotechnology use: Agriculture and Forestry;Companies;24.8
% Units by final application areas of biotechnology use: Agriculture and Forestry;NPPI;7.7
% Units by final application areas of biotechnology use: Environment;Total;20.9
% Units by final application areas of biotechnology use: Environment;Public Administration;23.5
% Units by final application areas of biotechnology use: Environment;Higher Education;76.5
% Units by final application areas of biotechnology use: Environment;Companies;18.2
% Units by final application areas of biotechnology use: Environment;NPPI;30.8
% Units by final application areas of biotechnology use: Industry;Total;15.7
% Units by final application areas of biotechnology use: Industry;Public Administration;15.1
% Units by final application areas of biotechnology use: Industry;Higher Education;70.6
% Units by final application areas of biotechnology use: Industry;Companies;13.5
% Units by final application areas of biotechnology use: Industry;NPPI;7.7
R&D personnel in Biotechnology (PP);Total;54,261
R&D personnel in Biotechnology (PP);Public Administration;16,196
R&D personnel in Biotechnology (PP);Higher Education;18,508
R&D personnel in Biotechnology (PP);Companies;19,307
R&D personnel in Biotechnology (PP);NPPI;250
R&D personnel in Biotechnology (PP): Research personnel;Total;34,806
R&D personnel in Biotechnology (PP): Research personnel;Public Administration;9,453
R&D personnel in Biotechnology (PP): Research personnel;Higher Education;14,417
R&D personnel in Biotechnology (PP): Research personnel;Companies;10,779
R&D personnel in Biotechnology (PP): Research personnel;NPPI;157
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;19,455
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Public Administration;6,743
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Higher Education;4,091
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Companies;8,528
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;NPPI;93
R&D personnel in Biotechnology (PP). Women;Total;31,521
R&D personnel in Biotechnology (PP). Women;Public Administration;10,361
R&D personnel in Biotechnology (PP). Women;Higher Education;9,841
R&D personnel in Biotechnology (PP). Women;Companies;11,155
R&D personnel in Biotechnology (PP). Women;NPPI;164
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;19,227
R&D personnel in Biotechnology (PP). Women: Research personnel;Public Administration;5,763
R&D personnel in Biotechnology (PP). Women: Research personnel;Higher Education;7,437
R&D personnel in Biotechnology (PP). Women: Research personnel;Companies;5,934
R&D personnel in Biotechnology (PP). Women: Research personnel;NPPI;93
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;12,295
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Public Administration;4,598
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Higher Education;2,404
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Companies;5,222
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;NPPI;71
R&D personnel in Biotechnology (FTE);Total;39,780.6
R&D personnel in Biotechnology (FTE);Public Administration;13,083.5
R&D personnel in Biotechnology (FTE);Higher Education;12,414.8
R&D personnel in Biotechnology (FTE);Companies;14,093.7
R&D personnel in Biotechnology (FTE);NPPI;188.6
R&D personnel in Biotechnology (FTE): Research personnel;Total;25,414.2
R&D personnel in Biotechnology (FTE): Research personnel;Public Administration;7,515.4
R&D personnel in Biotechnology (FTE): Research personnel;Higher Education;9,705.9
R&D personnel in Biotechnology (FTE): Research personnel;Companies;8,073.8
R&D personnel in Biotechnology (FTE): Research personnel;NPPI;119.1
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;14,366.4
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Public Administration;5,568.1
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Higher Education;2,708.9
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Companies;6,019.9
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;NPPI;69.5
R&D personnel in Biotechnology (FTE). Women;Total;23,767.2
R&D personnel in Biotechnology (FTE). Women;Public Administration;8,412.7
R&D personnel in Biotechnology (FTE). Women;Higher Education;6,920.0
R&D personnel in Biotechnology (FTE). Women;Companies;8,305.8
R&D personnel in Biotechnology (FTE). Women;NPPI;128.7
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;14,450.6
R&D personnel in Biotechnology (FTE). Women: Research personnel;Public Administration;4,618.2
R&D personnel in Biotechnology (FTE). Women: Research personnel;Higher Education;5,276.0
R&D personnel in Biotechnology (FTE). Women: Research personnel;Companies;4,482.6
R&D personnel in Biotechnology (FTE). Women: Research personnel;NPPI;73.9
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;9,316.5
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Public Administration;3,794.5
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Higher Education;1,644.0
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Companies;3,823.2
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;NPPI;54.8
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;3,143,765
Expenditure on internal R&D in Biotechnology (thousands of euros);Public Administration;972,158
Expenditure on internal R&D in Biotechnology (thousands of euros);Higher Education;697,028
Expenditure on internal R&D in Biotechnology (thousands of euros);Companies;1,462,695
Expenditure on internal R&D in Biotechnology (thousands of euros);NPPI;11,884
1) By type of expenditure: Current expenditure;Total;2,902,871
1) By type of expenditure: Current expenditure;Public Administration;903,064
1) By type of expenditure: Current expenditure;Higher Education;640,701
1) By type of expenditure: Current expenditure;Companies;1,347,574
1) By type of expenditure: Current expenditure;NPPI;11,531
1.1) Labour expenditure of research personnel;Total;1,209,348
1.1) Labour expenditure of research personnel;Public Administration;321,004
1.1) Labour expenditure of research personnel;Higher Education;413,619
1.1) Labour expenditure of research personnel;Companies;470,714
1.1) Labour expenditure of research personnel;NPPI;4,012
1.2) Labour expenditure of technical and auxiliary personnel;Total;573,196
1.2) Labour expenditure of technical and auxiliary personnel;Public Administration;216,529
1.2) Labour expenditure of technical and auxiliary personnel;Higher Education;95,990
1.2) Labour expenditure of technical and auxiliary personnel;Companies;258,791
1.2) Labour expenditure of technical and auxiliary personnel;NPPI;1,885
1.3) Other current expenditure;Total;1,120,327
1.3) Other current expenditure;Public Administration;365,530
1.3) Other current expenditure;Higher Education;131,093
1.3) Other current expenditure;Companies;618,069
1.3) Other current expenditure;NPPI;5,634
2) By type of expenditure: Capital expenditure;Total;240,894
2) By type of expenditure: Capital expenditure;Public Administration;69,094
2) By type of expenditure: Capital expenditure;Higher Education;56,327
2) By type of expenditure: Capital expenditure;Companies;115,121
2) By type of expenditure: Capital expenditure;NPPI;353
2.1) Land and buildings;Total;38,604
2.1) Land and buildings;Public Administration;5,531
2.1) Land and buildings;Higher Education;11,195
2.1) Land and buildings;Companies;21,877
2.1) Land and buildings;NPPI;0
2.2) Equipment and tools;Total;155,712
2.2) Equipment and tools;Public Administration;60,403
2.2) Equipment and tools;Higher Education;40,502
2.2) Equipment and tools;Companies;54,592
2.2) Equipment and tools;NPPI;216
2.3) Acquisition of specific R&D software;Total;8,005
2.3) Acquisition of specific R&D software;Public Administration;2,621
2.3) Acquisition of specific R&D software;Higher Education;573
2.3) Acquisition of specific R&D software;Companies;4,673
2.3) Acquisition of specific R&D software;NPPI;137
2.4) Other R&D-specific IP products;Total;38,574
2.4) Other R&D-specific IP products;Public Administration;539
2.4) Other R&D-specific IP products;Higher Education;4,057
2.4) Other R&D-specific IP products;Companies;33,978
2.4) Other R&D-specific IP products;NPPI;0
1.1) By origin of funds: Own funds;Total;1,307,305
1.1) By origin of funds: Own funds;Public Administration;183,045
1.1) By origin of funds: Own funds;Higher Education;107,514
1.1) By origin of funds: Own funds;Companies;1,013,505
1.1) By origin of funds: Own funds;NPPI;3,241
1.2) By origin of funds: Funds from the Business sector;Total;413,439
1.2) By origin of funds: Funds from the Business sector;Public Administration;155,843
1.2) By origin of funds: Funds from the Business sector;Higher Education;49,506
1.2) By origin of funds: Funds from the Business sector;Companies;206,072
1.2) By origin of funds: Funds from the Business sector;NPPI;2,019
1.3) By origin of funds: Funds from the Public Administration sector;Total;1,029,186
1.3) By origin of funds: Funds from the Public Administration sector;Public Administration;412,019
1.3) By origin of funds: Funds from the Public Administration sector;Higher Education;456,838
1.3) By origin of funds: Funds from the Public Administration sector;Companies;158,706
1.3) By origin of funds: Funds from the Public Administration sector;NPPI;1,623
1.4) By origin of funds: Funds from the Higher Education sector;Total;4,564
1.4) By origin of funds: Funds from the Higher Education sector;Public Administration;1,269
1.4) By origin of funds: Funds from the Higher Education sector;Higher Education;2,665
1.4) By origin of funds: Funds from the Higher Education sector;Companies;615
1.4) By origin of funds: Funds from the Higher Education sector;NPPI;15
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;64,269
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Public Administration;35,037
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Higher Education;18,402
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Companies;9,828
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;NPPI;1,002
1.6) By origin of funds: Funds from the rest of the world;Total;325,002
1.6) By origin of funds: Funds from the rest of the world;Public Administration;184,945
1.6) By origin of funds: Funds from the rest of the world;Higher Education;62,104
1.6) By origin of funds: Funds from the rest of the world;Companies;73,969
1.6) By origin of funds: Funds from the rest of the world;NPPI;3,984
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;166,144
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Public Administration;61,567
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Higher Education;8,234
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Companies;96,238
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);NPPI;104
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;126,704
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Public Administration;53,361
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Higher Education;7,875
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Companies;65,364
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;NPPI;104
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;39,440
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Public Administration;8,206
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Higher Education;360
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Companies;30,874
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;NPPI;0
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;47.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Public Administration;59.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Higher Education;52.9
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Companies;46.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;NPPI;76.9
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;16.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Public Administration;10.9
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Higher Education;11.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Companies;17.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;NPPI;7.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;27.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Public Administration;44.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Higher Education;35.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Companies;25.9
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;NPPI;15.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;14.9
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Public Administration;24.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Higher Education;35.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Companies;13.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;NPPI;7.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;19.9
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Public Administration;26.9
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Higher Education;41.2
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Companies;18.6
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;NPPI;15.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;19.0
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Public Administration;31.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Higher Education;39.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Companies;17.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;NPPI;7.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;18.9
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Public Administration;9.2
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Higher Education;8.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Companies;20.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;NPPI;23.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;47.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Public Administration;47.9
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Higher Education;38.2
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Companies;47.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;NPPI;53.9
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;54.0
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Public Administration;55.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Higher Education;57.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Companies;53.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;NPPI;61.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;21.6
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Public Administration;23.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Higher Education;17.6
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Companies;21.6
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;NPPI;23.1